UK Meningitis Outbreak: Symptoms, Vaccine & What You Need to Know

A meningitis B outbreak in the United Kingdom is raising concerns among health officials, with at least 27 confirmed and suspected cases reported in Kent, and two deaths confirmed as of Thursday, March 20, 2026. The outbreak is particularly affecting young people, with many cases linked to exposure at nightclubs.

Meningococcal group B disease, or MenB, is a severe bacterial infection caused by Neisseria meningitidis. According to Dr. Leana Wen, an emergency physician and clinical associate professor at George Washington University, and former Baltimore health commissioner, the infection can lead to meningitis – inflammation of the brain and spinal cord – or septicemia, a bloodstream infection. Both conditions are medical emergencies, with the potential for rapid and critical illness.

The current outbreak in Kent has been described as “unusually large” by Dr. Shira Doron, chief infection control officer at Tufts Medicine, indicating a faster concentration of cases than typically observed. Health officials are working to identify close contacts of those infected and limit further spread. Preventive antibiotics are being offered to close contacts of confirmed or suspected cases, as well as students at the University of Kent’s Canterbury Campus, and some staff living or working in those halls of residence.

Even as invasive meningococcal disease can be fatal in 8% to 15% of cases, even with treatment, survivors may experience long-term complications including hearing loss, neurological damage, or limb loss. The bacteria spreads through respiratory and throat secretions, requiring close or prolonged contact such as kissing or sharing drinks. It is not spread through casual contact.

We find three main age groups at peak risk for meningococcal disease: infants, adolescents and young adults, and adults over 65. Adolescents and young adults are more likely to carry the bacteria and frequent environments with close contact, such as shared housing and social gatherings. Certain medical conditions, including immune system disorders and HIV infection, also increase risk.

Early symptoms of MenB can resemble common illnesses, including fever, headache, fatigue, nausea, vomiting, and muscle aches. However, the disease can progress rapidly, leading to severe headache, stiff neck, sensitivity to light, confusion, difficulty staying awake, or seizures. A rash that does not fade when pressed is a key warning sign, though not everyone develops one. Other concerning signs include very cold hands and feet, rapid breathing, and changes in mental status.

If meningococcal disease is suspected, immediate medical attention is crucial. Clinicians often begin antibiotics immediately, even before confirming a diagnosis, due to the rapid progression of the illness. Exposure to the bacteria is handled by recommending preventative antibiotics for close contacts, such as household members or intimate partners.

In the UK, the MenB vaccine is recommended for babies at 8 weeks and 12 weeks old, with a booster at 1 year old. In the United States, there are three categories of meningococcal vaccines: MenACWY, which protects against groups A, C, W, and Y. MenB, which protects specifically against group B; and a newer combination vaccine protecting against all five major groups. The US Centers for Disease Control and Prevention recommends MenB vaccination for individuals 10 and older at increased risk, and offers it to otherwise healthy adolescents and young adults ages 16 to 23 based on shared clinical decision-making.

Health Secretary Wes Streeting warned on Thursday that the number of cases could “increase further in the coming days” due to the disease’s incubation period. The UK Health Security Agency (UKHSA) is continuing to monitor the situation and provide updates on case numbers.